Terms: = Germ cell tumor AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
282 results:
1. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
2. Aberrant atm signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
[TBL] [Abstract] [Full Text] [Related]
3. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.
Cordero-Hernandez IS; Ross AC; Dasari A; Halperin DM; Chasen B; Yao JC
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38329269
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Novel, Selective ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L
J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388
[TBL] [Abstract] [Full Text] [Related]
5. Nivolumab Plus Ipilimumab in Patients With Solid tumors With
Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
[TBL] [Abstract] [Full Text] [Related]
6. Invasion-Block and S-MARVEL: A high-content screening and image analysis platform identifies atm kinase as a modulator of melanoma invasion and metastasis.
Guo D; Jurek R; Beaumont KA; Sharp DS; Tan SY; Mariana A; Failes TW; Grootveld AK; Bhattacharyya ND; Phan TG; Arndt GM; Jain R; Weninger W; Tikoo S
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2303978120. PubMed ID: 37963252
[TBL] [Abstract] [Full Text] [Related]
7. Reasoning and causal inference regarding surgical options for patients with low-grade gliomas using machine learning: A SEER-based study.
Zhu E; Shi W; Chen Z; Wang J; Ai P; Wang X; Zhu M; Xu Z; Xu L; Sun X; Liu J; Xu X; Shan D
Cancer Med; 2023 Nov; 12(22):20878-20891. PubMed ID: 37929878
[TBL] [Abstract] [Full Text] [Related]
8. [Systemic therapies for advanced thyroid cancer - an update].
Brandenburg T; Machlah YM; Führer-Sakel D
Dtsch Med Wochenschr; 2023 Nov; 148(22):1412-1418. PubMed ID: 37918424
[TBL] [Abstract] [Full Text] [Related]
9. Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.
Němčíková P; Brunerová L
Vnitr Lek; 2023; 69(5):312-315. PubMed ID: 37827829
[TBL] [Abstract] [Full Text] [Related]
10. Coexistence of longitudinally extensive transverse myelitis and diffuse midline glioma in the brainstem in an adolescent boy with acute flaccid paralysis.
Caliskan E; Sager SG; Yukselmis U; Kilic AK; Gunbey HP
Childs Nerv Syst; 2024 Jan; 40(1):227-232. PubMed ID: 37737897
[TBL] [Abstract] [Full Text] [Related]
11. PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction
Fröhlich LM; Niessner H; Sauer B; Kämereit S; Chatziioannou E; Riel S; Sinnberg T; Schittek B
Cancer Res Commun; 2023 Sep; 3(9):1743-1755. PubMed ID: 37674529
[TBL] [Abstract] [Full Text] [Related]
12. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
[TBL] [Abstract] [Full Text] [Related]
13. atm-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis.
Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B
Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496
[TBL] [Abstract] [Full Text] [Related]
14. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERate in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Federico S; Gatz SA; Ortiz M; Lesa G; Scobie N; Gounaris I; Weiner SL; Weigel B; Unger TJ; Stewart E; Smith M; Slotkin EK; Reaman G; Pappo A; Nysom K; Norga K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Karres D; Kool M; Horner TJ; Henssen A; Heenen D; Hawkins DS; Gore L; Bender JG; Galluzzo S; Fox E; de Rojas T; Davies BR; Chakrabarti J; Carmichael J; Bradford D; Blanc P; Bernardi R; Benchetrit S; Akindele K; Vassal G
Eur J Cancer; 2023 Sep; 190():112950. PubMed ID: 37441939
[TBL] [Abstract] [Full Text] [Related]
15. Chrysin-Induced Regression of Angiogenesis via an Induction of DNA Damage Response and Oxidative Stress in In Vitro and In Vivo Models of Melanoma.
Sassi A; Fredon M; Cotte AK; Fuselier C; Schneider C; Martiny L; Monchaud D; Chekir-Ghedira L; Aires V; Delmas D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371032
[TBL] [Abstract] [Full Text] [Related]
16. Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Patrick S; Lathoria K; Suri V; Sen E
Cell Signal; 2023 Sep; 109():110738. PubMed ID: 37269960
[TBL] [Abstract] [Full Text] [Related]
17. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
18. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract] [Full Text] [Related]
19. atm depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors.
Parvin S; Akter J; Takenobu H; Katai Y; Satoh S; Okada R; Haruta M; Mukae K; Wada T; Ohira M; Ando K; Kamijo T
BMC Cancer; 2023 Apr; 23(1):313. PubMed ID: 37020276
[TBL] [Abstract] [Full Text] [Related]
20. atm inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
Xie J; Kuriakose T; Bianski B; Twarog N; Savage E; Xu K; Zhu X; He C; Hansen B; Wang H; High A; Li Y; Rehg JE; Tillman HS; Freeman BB; Rankovic Z; Onar-Thomas A; Fan Y; Wu G; Peng J; Miller S; Baker SJ; Shelat AA; Tinkle CL
Neuro Oncol; 2023 Oct; 25(10):1828-1841. PubMed ID: 36971093
[TBL] [Abstract] [Full Text] [Related]
[Next]
